compare this with the almost flat GFR slope from interim telitacicept data (while we await atacicept aka Trutakna data) www.nephjc.com/news/2026/sh... from @nephromommy-akshu.bsky.social
Akshaya Jayachandran
@nephromommy-akshu.bsky.social
MD Internal Medicine, PGI Chandigarh DM Nephrology, CMC Vellore, India 🇮🇳 Passionate nephrologist ! 🩺 👩🏻⚕️ Perspicacious toddler mom ! 👩🏻🍼
9/10 I want more info Blog by @nephromommy-akshu.bsky.social @nephroseeker.medsky.social www.nephjc.com/news/2026-impact-bp VA by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/5/18/impacts-bp-the-visual-abstract
IMPACTS-BP: The Visual Abstract — NephJC
Can multifaceted strategies improve hypertension control in low-income patients? Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood press...
nephjc.com
✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...
NephJC Internship 2026-2027 — NephJC
Introducing NephJC’s brand new editorial internship class of 2026-2027
nephjc.com
👂So, did you hear the one about avacopan and data manipulation? 🧮🧮🧮 @hswapnil.medsky.social has added onto our ADVOCATE summary with a "postscript" review of the controversies. #NephSky #MedSky www.nephjc.com/news/advocate?rq=avacopan
Advocating for Patients with Vasculitis: A Steroid-Sparing Regimen with Avacopan — NephJC
This week, we will discuss the ADVOCATE trial. Avacopan is not just a flash in the pan? We hope so, having won the RheumMadness and offering a steroid free hope.
nephjc.com
Do you struggle with FSGS? Are you a sparsentan fan but asking, what's next? TRPC6 inhibitors completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? Blog by @drsaivani.bsky.social & @sayalibthakare.bsky.social #NephSky #MedSky www.nephjc.com/news/trcpc6inhibition-fsgs
Is TRPC6 inhibition for FSGS a trick or a treat? — NephJC
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterog...
nephjc.com
1/ Hey #NephSky! 👋 We’re back with a fresh #Skytorial by @nephromommy-akshu.bsky.social We spend half our lives worrying about how bad creatinine is.. then keep using it anyway. What if we could measure bedside GFR - no serial blood samples? Let’s talk transdermal GFR (tGFR). @theisn.org
#NephJC The #TenPostNephJC on REACT injections in DKD is live !! Missed the chat? Need a short recap of the study ? We’ve got you covered !! 😃
Nephrology Journal Club@nephjc.bsky.social · 5mo ago1/10 Welcome to #TenPostNephJC Can we move beyond slowing CKD → to actually repairing the kidney? Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.
Are you attending the @theisn.org WCN 2026? Don’t miss the KDIGO activities at this year’s congress. See the flyers for key details, and be sure to visit KDIGO at booth #26. Learn more about the KDIGO GEM Satellite Symposium: kdigo.co/WCN26-GEM #ISNWCN program: www.theisn.org/wcn/program-...
Everything said and done, once it reaches clinical practice - implementation is going to be pretty hard, coz the already established treatments are much simpler. And getting a patient to agree to an invasive procedure like a renal biopsy is gonna be next to impossible ! #NephJC
We're discussing 💉REACT- renal autologous cell treatments (rilprencel) in diabetic kidney disease. Is regenerative medicine the future of nephrology❓ Come discuss 3/10/26 at 9pm #NephJC #NephSky Blog by @drsaivani.bsky.social and @nephromommy-akshu.bsky.social www.nephjc.com/news/rilprencel-react
Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease? — NephJC
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
nephjc.com
Hey #NephJC I’m Akshaya J, from Vellore India - glad to be here ! Currently, we’re not able to construct the DKD Building coz most of our patients can’t afford the 4 pillars of DKD!! 2 pillars are our usual practice 😅 !! 5th pillar ? Seems like a fantasy 😇 !! WKD2026 going full throttle at CMC !
What is the group’s experience on Oral Iron + continuing ESAs while TSAT < 20%. Definitely not ideal, still I would like to know. Or traditional IV formulations like Iron Sucrose? #NephJC
Hey all, This is Akshaya, junior Nephrologist from India, #NephJC intern and aggressive HIF-PHI prescriber !! Got late, despite the multiple reminders ⏰ on my phone !! Apologies!
✨It's that time of the year again, to nominate the most deserving people in our community for #NephJCKidneys award 👇Here's a reminder of previous winners 📌You can nominate worthy individuals/ initiatives by using the hashtag or by using the form www.nephjc.com/news/... #NephJC
Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
INFINITI: The Visual Abstract — NephJC
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in...
nephjc.com
T -15min 👉Before we start, a few reminders! Are you new to #NephJC? Not sure what to do or how this works? Here is a quick rundown, an infographic made by Sinead Stoneman
⏰2 hours until #NephJC chat SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat. 1/2
Hey #NephSky 2/10/26 at 9 pm EST we'll discuss #Flozinating into the Future & Beyond... SGLT2i in kidney transplant recipients. What's the latest evidence of risk/benefit? Do #Flozins act mechanistically the same in de-innervated kidneys? Come chat. www.nephjc.com/news/inifinti-flozins-transplant
To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients — NephJC
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
nephjc.com
Potassium sits at the center of physician anxiety 😟 Tonight, we ask a provocative question with POTCAST 👉 Are we really targeting the “correct” potassium range? #NephJC
Oh, the weather outside is frightful 🥶🥶 But #NephJC is so delightful, and since you've no place to go #NephSky... Come discuss POTCAST: potassium goals and cardiac arrhythmias 1/27/26 at 9pm EST on #Bluesky Summary by @shelliefravel.bsky.social @salinesolut.bsky.social www.nephjc.com/news/potcast
POTCAST- K+ Pop and Arrhythmia Drop — NephJC
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
nephjc.com
6/10 Give me something clever to say 🤓 @nephromommy-akshu.bsky.social bsky.app/profile/neph...
Akshaya Jayachandran@nephromommy-akshu.bsky.social · 7mo agoIn many other glomerular diseases, 2g/g proteinuria at baseline does get well controlled with ARB/ SGLT2i and MMF, but in this trial they don’t seem to be very effective. So Pegcetacoplan seems to be pretty effective compared to SOC ! Across subgroups and even in adolescents! #NephJC
Hey #NephJC friends! Sayali here, from Mumbai! Perplexed and vexed by this disease. Waiting for a cure, & more importantly, waiting for the cure to be shipped to India! Good job on the abstract @nephromommy-akshu.bsky.social & summary @drsaivani.bsky.social ! 👍🏻
T0b The pathophysiology of C3GN & IC-MPGN is thought to be caused by: Genetic mutations or Acquired defect of complement proteins or Auto-antibodies against complement factors and/or regulating proteins. #NephJC
⏰2 hours until #NephJC chat Join us today to learn more about the recently released VALIANT study, which investigates the use of Pegcetacoplan in C3 glomerulonephropathy and immune complex mediated glomerulonephritis
We will be discussing C3G today - so review the disease and the journey so far with Prof Carla Nester: youtu.be/Fo6J__RgWA0?... From our #NephGR a few months ago Excellent crisp overview of the science!
C3 Glomerulopathy: The Promise of a targeted therapy with Prof. Carla Nester
YouTube video by Ottawa Nephrology
youtu.be
Check out the VA for VALIANT from @nephromommy-akshu.bsky.social #NephJC www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract
VALIANT: The Visual Abstract — NephJC
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-com...
nephjc.com